THE ROLE OF THE PHARMACIST TO BETTER FRAMEWORK FOR THE SAFETY OF SIBUTRAMIN FOR THE CONTROL OF OBESITY IN CHILDREN

Detalhes bibliográficos
Autor(a) principal: Claudino, Patrícia Andrade
Data de Publicação: 2021
Outros Autores: Balbino, Michelle Lucas Cardoso
Tipo de documento: Artigo
Idioma: por
Título da fonte: Scientia Generalis
Texto Completo: https://scientiageneralis.com.br/index.php/SG/article/view/170
Resumo: It is a consensus that obesity in childhood and adolescence has increased significantly in recent decades, making it a worrying case in global health. Obesity is a pathology of the group of Chronic Non-Communicable Diseases (NCDs) which can be defined as a disease characterized by excessive increase in fat (TARDIDO; FALCÃO, 2006). Pharmacological therapy is recommended as an adjunct tool for obese or overweight patients who may be associated with life-threatening comorbidities. Anti-obesity drugs generally act by decreasing appetite, inhibiting fat absorption or increasing energy consumption and thermogenesis, and also on neurotransmission systems. Among the drugs used as slimming, we can highlight: Sibutramine, Sertraline and Fluoxetine. This article aims to understand the role of the pharmacist, given the situation of their client-patient in the use of sibutramine, thus contributing to a better control and dosage of appetite, bringing satisfactory results to combat obesity. The benefits of using pharmacological agents are to promote increased patient adherence to nutritional and behavioral changes, in addition to weight loss and improved life. For that, a descriptive research with a qualitative approach of literature review was used.
id INDEP-1_5c5d5c91217d1bf00a8f44b931786e81
oai_identifier_str oai:ojs2.scientiageneralis.com.br:article/170
network_acronym_str INDEP-1
network_name_str Scientia Generalis
repository_id_str
spelling THE ROLE OF THE PHARMACIST TO BETTER FRAMEWORK FOR THE SAFETY OF SIBUTRAMIN FOR THE CONTROL OF OBESITY IN CHILDRENEL PAPEL DEL FARMACÉUTICO PARA MEJORAR EL MARCO DE SEGURIDAD DE LA SIBUTRAMINA PARA EL CONTROL DE LA OBESIDAD EN NIÑOSO PAPEL DO FARMACÊUTICO PARA O MELHOR ENQUADRAMENTO DA SEGURANÇA DE SIBUTRAMINA PARA O CONTROLE DE OBESIDADE DE INFANTOJUVENILSibutramina; Obesidad; Infanto Juvenil.Sibutramine; Obesity; Children and Youth. SibutraminaObesidadeInfantojuvenilIt is a consensus that obesity in childhood and adolescence has increased significantly in recent decades, making it a worrying case in global health. Obesity is a pathology of the group of Chronic Non-Communicable Diseases (NCDs) which can be defined as a disease characterized by excessive increase in fat (TARDIDO; FALCÃO, 2006). Pharmacological therapy is recommended as an adjunct tool for obese or overweight patients who may be associated with life-threatening comorbidities. Anti-obesity drugs generally act by decreasing appetite, inhibiting fat absorption or increasing energy consumption and thermogenesis, and also on neurotransmission systems. Among the drugs used as slimming, we can highlight: Sibutramine, Sertraline and Fluoxetine. This article aims to understand the role of the pharmacist, given the situation of their client-patient in the use of sibutramine, thus contributing to a better control and dosage of appetite, bringing satisfactory results to combat obesity. The benefits of using pharmacological agents are to promote increased patient adherence to nutritional and behavioral changes, in addition to weight loss and improved life. For that, a descriptive research with a qualitative approach of literature review was used.Existe un consenso de que la obesidad en la infancia y la adolescencia ha aumentado significativamente en las últimas décadas, lo que la convierte en un caso preocupante en la salud global. La obesidad es una patología del grupo de las Enfermedades Crónicas No Transmisibles (ENT) que se puede definir como una enfermedad caracterizada por un aumento excesivo de grasa. La terapia farmacológica se recomienda como una herramienta complementaria para pacientes obesos o con sobrepeso, que pueden estar asociados con comorbilidades potencialmente mortales. Los medicamentos contra la obesidad generalmente actúan disminuyendo el apetito, inhibiendo la absorción de grasas o aumentando el consumo de energía y la termogénesis, y también sobre los sistemas de neurotransmisión. Entre los fármacos utilizados como adelgazantes, podemos destacar: Sibutramina, Sertralina y Fluoxetina. Este artículo tiene como objetivo comprender el papel del farmacéutico, dada la situación de su cliente-paciente en el uso de la sibutramina, contribuyendo así a un mejor control y dosificación del apetito, aportando resultados satisfactorios para combatir la obesidad. Los beneficios del uso de agentes farmacológicos son promover una mayor adherencia del paciente a los cambios nutricionales y de comportamiento, además de la pérdida de peso y una mejor vida. Para eso, se utilizó una investigación descriptiva con un enfoque cualitativo de revisión de la literatura.É consenso que a obesidade na infância e adolescência vem aumentando de forma significativa nas últimas décadas, tornando-se um caso preocupante na saúde mundial. A obesidade é uma patologia do grupo de Doenças Crônicas não Transmissíveis (DCNT) que pode ser definida como uma doença caraterizada pelo aumento excessivo de gordura. A terapia farmacológica é recomendada como uma ferramenta adjuvante para pacientes obesos ou que apresentam sobrepeso, que podem estar associadas com comorbidades que colocam suas vidas em risco. Os fármacos antiobesidade geralmente atuam diminuindo o apetite, inibindo absorção de gordura ou aumentando o consumo de energia e termogênese, e também em sistemas de neurotransmissão. Dentre os medicamentos utilizados como emagrecedores, podemos destacar: Sibutramina, Sertralina e a Fluoxetina. O presente artigo tem como objetivo conhecer o papel do farmacêutico, diante da situação do seu cliente-paciente no uso da sibutramina, contribuindo, assim, para um melhor controle e dosagem do apetite, trazendo resultados satisfatórios para o combate à obesidade. Os benefícios da utilização de agentes farmacológicos consistem em promover um aumento da aderência dos pacientes a mudanças nutricionais e comportamentais, além da perda de peso e melhoria de vida. Para tanto, foi utilizada uma pesquisa descritiva com abordagem qualitativa de revisão de literatura.Scientia GeneralisScientia GeneralisScientia Generalis2021-08-24info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://scientiageneralis.com.br/index.php/SG/article/view/170Scientia Generalis; v. 2 n. 2 (2021); 60-74Scientia Generalis; Vol. 2 No. 2 (2021); 60-74Scientia Generalis; Vol. 2 Núm. 2 (2021); 60-742675-299927363/v2n2reponame:Scientia Generalisinstname:Publicação independenteinstacron:INDEPporhttps://scientiageneralis.com.br/index.php/SG/article/view/170/130Copyright (c) 2021 Patrícia Andrade Claudino, Michelle Lucas Cardoso Balbinohttps://creativecommons.org/licenses/by-sa/4.0info:eu-repo/semantics/openAccessClaudino, Patrícia AndradeBalbino, Michelle Lucas Cardoso 2023-08-01T03:32:05Zoai:ojs2.scientiageneralis.com.br:article/170Revistahttps://scientiageneralis.com.br/index.php/SGPRIhttps://scientiageneralis.com.br/index.php/SG/oaieditor@scientiageneralis.com.br2675-29992675-2999opendoar:2023-08-01T03:32:05Scientia Generalis - Publicação independentefalse
dc.title.none.fl_str_mv THE ROLE OF THE PHARMACIST TO BETTER FRAMEWORK FOR THE SAFETY OF SIBUTRAMIN FOR THE CONTROL OF OBESITY IN CHILDREN
EL PAPEL DEL FARMACÉUTICO PARA MEJORAR EL MARCO DE SEGURIDAD DE LA SIBUTRAMINA PARA EL CONTROL DE LA OBESIDAD EN NIÑOS
O PAPEL DO FARMACÊUTICO PARA O MELHOR ENQUADRAMENTO DA SEGURANÇA DE SIBUTRAMINA PARA O CONTROLE DE OBESIDADE DE INFANTOJUVENIL
title THE ROLE OF THE PHARMACIST TO BETTER FRAMEWORK FOR THE SAFETY OF SIBUTRAMIN FOR THE CONTROL OF OBESITY IN CHILDREN
spellingShingle THE ROLE OF THE PHARMACIST TO BETTER FRAMEWORK FOR THE SAFETY OF SIBUTRAMIN FOR THE CONTROL OF OBESITY IN CHILDREN
Claudino, Patrícia Andrade
Sibutramina; Obesidad; Infanto Juvenil.
Sibutramine; Obesity; Children and Youth.
Sibutramina
Obesidade
Infantojuvenil
title_short THE ROLE OF THE PHARMACIST TO BETTER FRAMEWORK FOR THE SAFETY OF SIBUTRAMIN FOR THE CONTROL OF OBESITY IN CHILDREN
title_full THE ROLE OF THE PHARMACIST TO BETTER FRAMEWORK FOR THE SAFETY OF SIBUTRAMIN FOR THE CONTROL OF OBESITY IN CHILDREN
title_fullStr THE ROLE OF THE PHARMACIST TO BETTER FRAMEWORK FOR THE SAFETY OF SIBUTRAMIN FOR THE CONTROL OF OBESITY IN CHILDREN
title_full_unstemmed THE ROLE OF THE PHARMACIST TO BETTER FRAMEWORK FOR THE SAFETY OF SIBUTRAMIN FOR THE CONTROL OF OBESITY IN CHILDREN
title_sort THE ROLE OF THE PHARMACIST TO BETTER FRAMEWORK FOR THE SAFETY OF SIBUTRAMIN FOR THE CONTROL OF OBESITY IN CHILDREN
author Claudino, Patrícia Andrade
author_facet Claudino, Patrícia Andrade
Balbino, Michelle Lucas Cardoso
author_role author
author2 Balbino, Michelle Lucas Cardoso
author2_role author
dc.contributor.author.fl_str_mv Claudino, Patrícia Andrade
Balbino, Michelle Lucas Cardoso
dc.subject.por.fl_str_mv Sibutramina; Obesidad; Infanto Juvenil.
Sibutramine; Obesity; Children and Youth.
Sibutramina
Obesidade
Infantojuvenil
topic Sibutramina; Obesidad; Infanto Juvenil.
Sibutramine; Obesity; Children and Youth.
Sibutramina
Obesidade
Infantojuvenil
description It is a consensus that obesity in childhood and adolescence has increased significantly in recent decades, making it a worrying case in global health. Obesity is a pathology of the group of Chronic Non-Communicable Diseases (NCDs) which can be defined as a disease characterized by excessive increase in fat (TARDIDO; FALCÃO, 2006). Pharmacological therapy is recommended as an adjunct tool for obese or overweight patients who may be associated with life-threatening comorbidities. Anti-obesity drugs generally act by decreasing appetite, inhibiting fat absorption or increasing energy consumption and thermogenesis, and also on neurotransmission systems. Among the drugs used as slimming, we can highlight: Sibutramine, Sertraline and Fluoxetine. This article aims to understand the role of the pharmacist, given the situation of their client-patient in the use of sibutramine, thus contributing to a better control and dosage of appetite, bringing satisfactory results to combat obesity. The benefits of using pharmacological agents are to promote increased patient adherence to nutritional and behavioral changes, in addition to weight loss and improved life. For that, a descriptive research with a qualitative approach of literature review was used.
publishDate 2021
dc.date.none.fl_str_mv 2021-08-24
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://scientiageneralis.com.br/index.php/SG/article/view/170
url https://scientiageneralis.com.br/index.php/SG/article/view/170
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://scientiageneralis.com.br/index.php/SG/article/view/170/130
dc.rights.driver.fl_str_mv Copyright (c) 2021 Patrícia Andrade Claudino, Michelle Lucas Cardoso Balbino
https://creativecommons.org/licenses/by-sa/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2021 Patrícia Andrade Claudino, Michelle Lucas Cardoso Balbino
https://creativecommons.org/licenses/by-sa/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Scientia Generalis
Scientia Generalis
Scientia Generalis
publisher.none.fl_str_mv Scientia Generalis
Scientia Generalis
Scientia Generalis
dc.source.none.fl_str_mv Scientia Generalis; v. 2 n. 2 (2021); 60-74
Scientia Generalis; Vol. 2 No. 2 (2021); 60-74
Scientia Generalis; Vol. 2 Núm. 2 (2021); 60-74
2675-2999
27363/v2n2
reponame:Scientia Generalis
instname:Publicação independente
instacron:INDEP
instname_str Publicação independente
instacron_str INDEP
institution INDEP
reponame_str Scientia Generalis
collection Scientia Generalis
repository.name.fl_str_mv Scientia Generalis - Publicação independente
repository.mail.fl_str_mv editor@scientiageneralis.com.br
_version_ 1797042484441776128

Registros relacionados